Clinical Trial Update: Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia [Phase 2]

View source ↗

Summary

This clinical trial update reports on the Phase 2 efficacy and safety evaluation of XueZhiKang (XZK), a lipid-lowering agent, in adults with hyperlipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia

Drugs mentioned

• XueZhiKang (XZK) (XZK)

Snippet

Sponsor: Beijing Peking University WBL Biotech Co., Ltd. | Conditions: Hyperlipidemia | Phase 2 | Status: COMPLETED